Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies

Anticancer Research

Volumn 28, Issue 5 A, 2008, Pages 2679-2686

  Patel, Dipa ^a   Bassi, Rajiv ^a   Hooper, Andrea T ^a   Sun, Haijun ^a   Huber, James ^a   Hicklin, Daniel J ^a   Kang, Xiaoqiang ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis; Anti TYRP 1 gp75; Anti VEGFR; Antibody therapy; Melanoma

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY TA 99; TA 99; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GROWTH INHIBITION; LUNG METASTASIS; MELANOMA; METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; OXIDOREDUCTASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 55749098806     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. American Cancer Society: Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society, 2008.
2. Lazar-Molnar E, Hegesi H, Toth S and Falus A: Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12: 547-554, 2000.
3. Luca MR and Bar-Eli M: Molecular changes in human melanoma metastasis. Histol Histopathol 13: 1225-1231, 1998.
4. Mahabeleshwar GH and Byzova TV: Angiogenesis in melanoma. Semin Oncol 34: 555-65, 2007.
5. Kawakami Y and Rosenberg SA: Human tumor antigens recognized by T-cells. Immunol Res 16: 313-339, 1997.
6. Kang X, Kawakami Y, El-Gamil M, Wang RF, Sakaguchi K, Yannelli JR, Appelle E, Rosenberg SA and Robbins PF: Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 155: 1443-1348, 1995.
7. Wang RF, Appella E, Kawakami Y, Kang X and Rosenberg SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes 184: 2207-2216, 1996.
8. Wang RF, Robbins PF, Kawakimi Y, Kang, X and Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181: 799-804, 1995
9. Kobayashi T, Urabe K, Winder A, Jimenez-Cervantes C, Imokawa G, Brewington T, Solano F, Garcia-Borron JC and Hearing VJ: Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. EMBO J 13: 5818-5825, 1994.
10. Vijayasaradhi S, Doskoch PM and Houghton AN: Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product. Exp Cell Res 196: 233-240, 1991
11. Xu Y, Vijayasaradhi S, Houghton AN: The cytoplasmic tail of the mouse brown locus product determines intracellular stability and export from the endoplasmic reticulum. J Invest Dermatol 110: 324-331, 1998
12. Takechi Y, Hara I, Naftzger C, Xu, Y and Houghton AN: A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 2: 1837-1842, 1996.
13. Thomas TM, Mattes, MJ, Roux L, Old LJ and Lloyd KO: Pigmentation- associated glycoprotein of human melanoma and melanocytes: definition with a mouse monoclonal antibody. J Invest Dermatol 85: 169-174, 1985.
14. Welt S, Mattes MJ, Grando R, Thomson TM, Leonard RW, Zanzonico PB, Bigler RE, Yeh S, Oettgen HF and Old LJ: Monoclonal antibody to an intracellular antigen images human melanoma in nu/nu mice. Proc Natl Aca Sci USA 84: 4200-4204, 1987.
15. Hara I, Takechi Y and Houghton AN: Implicating a role for immune recognition of self in tumor injection: passive immunization against the brown locus protein. J Exp Med 182: 1609-1614, 1995.
16. Clynes R, Takechi Y, Moroi Y, Houghton A and Ravetch JV: Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95: 652-656, 1998.
17. Birck A, Kirkin AF, Zeuthen J and Hou-Jensen K: Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res 9: 375-381, 1999.
18. Lin EY, Piepkorn M, Garcia R, Byrd D, Tsou R and Isik FF: Angiogenesis and vascular growth factor receptor expression in malignant melanoma. Plast Reconstr Surg 104: 1666-1674, 1999.
19. Neitzel LT, Neitzel CD, Magee KL and Malafa MP: Angiogenesis correlates with metastasis in melanoma. Ann Surg Oncol 6: 70-74, 1999.
20. Vlaykova T, Laurila P, Muhonen T, Hahka-Kemppinen M, Jekunen A, Alitalo K and Pyrhonen S: Prognostic value of tumour vascularity in metastatic melanoma and association of of blood vessel density with vascular endothelial growth factor expression. Melanoma Res 9: 59-68, 1999.
21. Kim K, Li B, Winer J, ArmaniniM, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond) 362: 841-844, 1993.
22. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Uilrich A, Hirth KP and McMahon G: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106, 1999.
23. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser, J, Hooper, A, Pytowski B, Witte L, Bohler P and Hicklin DJ: Antivascular endothelial growth factor receptor (fetal liver kinase I) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218, 1999.
24. Rockwell P, Neufeld G, Glassman A, Caron D and Goldstein NI: In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody. Mol Cell Differ 3: 91-109, 1995.
25. Vijayasaradhi S, Bouchard B and Houghton AN: The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 171: 1375-1380, 1990.
26. Jimbow K, Gomez PF, Toyofuku K, Chang D, Miura S, Tsujiya H and Park JS: Biological role of tyrosinase related protein and its biosynthesis and transport from TGN to stage I melanosome, late endosome, through gene transfection study. Pigment Cell Res 10: 206-213, 1997.
27. McDonald, DM, Munn L, and Jain RK: Vasculogenic mimicry: how convincing, how novel, and how significant? Am. J Pathol 156: 383-388, 2000.
28. Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, Smith GM and Forman J. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol 164: 217-222, 2000.
29. Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE and Hicklin DJ: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 12: 2197-207, 2006.
30. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, Drazan KE, Bucana CD, Hicklin DJ and Ellis LM: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85: 584-589, 2001.